Niederer Kraft Frey advised Stalicla on its series B financing.

Stalicla SA, a clinical-stage biopharmaceutical company advancing precision medicine pipelines for neuropsychiatric and neurological disorders has successfully completed the first closing of its series B financing round, securing USD 17.4 million.

Led by SPRIM Global Investments Pte, Ltd, with key participation from core investors, this financing includes a USD 3.8 million credit facility.

The proceeds will be utilised for: (i) preparation of Stalicla’s pioneering precision Autism Spectrum Disorder (ASD) Phase 2 trial – STP1; (ii) the establishment of its STP7 mGluR5 Negative Allosteric Modulator (mGluR5 NAM) platform, including the launch of a Phase III study in Substance Use Disorders (SUDs) slated for 2025, fully supported by the NIH /National Institute on Drug Abuse; (iii) the ramp up of its ongoing bio sampling/patient identification trial STA-B-001 currently enrolling in sites in the USA, Spain and Australia. Alongside these key developments, Stalicla will further strengthen the package supporting its second precision ASD asset, STP2.

The NKF team was led by Corporate/M&A and Life Sciences partner Jacques Bonvin, working with associate Boris Catzeflis (Corporate/M&A and Technology), and junior associate Robert Deprez-Fernandes (Corporate/M&A).